N/A N=527 DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
Cataract
Primary: Percentage of Eyes With Anterior Chamber Cell Grade 0 — 65 percentage of eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,105 The PIONEER-01 Study of the Imagio Breast Imaging System
Breast Cancer
Primary: Specificity Difference Between Imagio Optoacoustic Plus Gray-scale (OA/US) vs Imagio Gray-scale Ultrasound (IUS) — 14.9 % benign+TPB masses correctly Id'd
Phase 4 N=121 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
Multiple Myeloma
Primary: Percentage of Participants With ≥1 SRE at the End of 1 Year on Study — 0; 0.17 percentage of participants
N/A N=33 Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)
Chronic Obstructive Pulmonary Disease
Primary: Mean SpO2 (Oxygen Saturation) During Six Minute Walk Tests (6MWTs) — 91.2; 90.0 percentage of oxygen saturation
Phase 4 N=6 Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
Paget's Disease of the Bone
Primary: Percentage of Participants With Serum Alkaline Phosphatase Within the Normal Range at Month 6 Last Observation Carried Forward (LOCF) — 83.3 Percentage of Participants
N/A N=231 Lumbar Puncture and Syphilis Outcome
Syphilis
Primary: Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer — 38; 30 Participants — p=0.29
N/A N=134 Safety and Efficacy Study of the Evoke™ SCS System With Feedback vs. Conventional Stimulation
Chronic Pain · Back Pain · Pain
Primary: Number of Participants With Composite Endpoint Success — 51; 38 Participants — p=<0.001
Phase 1 N=18 A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
Dyslipidemias
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B — 0…
N/A N=184 Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy
Sleep Apnea · Diabetes
Primary: Change in Continuous Glucose Monitoring System Standard Deviation — 0.8; 1.1 mg/dL
Phase 3 N=536 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) — -1.27; -1.23 Percentage of HbA1c — p=0.545
Phase 2 N=58 Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
Lymphoma, Mantle- Cell
Primary: Overall Response Rate (ORR) — 8.6 percentage of participants
N/A N=44 A Pilot Study of Hand Function in Children With Cerebral Palsy Undergoing Intensive Neurophysiological Rehabilitation
Cerebral Palsy
Primary: Jebsen Taylor Hand Function Test for Dominant Hand — 130.1; 115.2 seconds
N/A N=11 Continue Glucose Monitoring Before Insulin Pump
Type 1 Diabetes Mellitus
Primary: Percentage Time Within Target Blood Glucose (Range: 70-180 mg/dL) — 81.7; 68.0 Percentage of time
Phase 2 N=6 Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
Breast Cancer
Primary: Number of Participants Experiencing Adverse Events — 6 Participants
Phase 2 N=38 Treating Smokers With Mental Illness
Smoking Cessation · Cigarette Smoking · Schizophrenia
Primary: 7-Day Point Prevalence Abstinence — 5; 3; 4; 5 Participants